Literature DB >> 27778334

Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis.

A Gouveia1, S P Dias2, T Santos3, H Rocha4,5, C R Coelho6, L Ruano7,8, O Galego9, M C Diogo10, D Seixas11,12, M J Sá4,13, S Batista1,14.   

Abstract

OBJECTIVES: To characterize cognitive impairment in primary progressive multiple sclerosis (PPMS) and to correlate the pattern of cognitive deficits with brain magnetic resonance imaging (MRI) volumetric data.
MATERIALS AND METHODS: In a multicenter cross-sectional study, we recruited consecutive patients with PPMS as well as age, sex, and education level-matched healthy controls (HC). All participants underwent neuropsychological (NP) assessment, and brain MRI was performed in patients with PPMS for analysis of lesion load, subcortical GM volumes, and regional cortical volumes.
RESULTS: We recruited 55 patients with PPMS and 36 HC. Thirty-six patients were included in the MRI analysis. Patients with PPMS performed significantly worse than HC in all NP tests. Subcortical GM volume was significantly correlated with all NP tests, except for Stroop Test, with the largest effect for the thalamus (r=-.516 [BVMT-R DR, P=.016 FDR-corrected] to r=.664 [SDMT, P<.001 FDR-corrected]). In the stepwise linear regression model, thalamic volume was the only predictor of performance in all NP tests.
CONCLUSION: Cognitive impairment is common in PPMS and affects all evaluated cognitive domains. Subcortical GM volume, particularly of the thalamus, is a strong predictor of cognitive performance, suggesting it has a central role in the pathophysiology of PPMS-related cognitive dysfunction.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cognitive impairment; magnetic resonance imaging; primary progressive multiple sclerosis; subcortical gray matter; thalamus

Mesh:

Year:  2016        PMID: 27778334     DOI: 10.1111/ane.12702

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  5 in total

1.  Localised grey matter atrophy in multiple sclerosis is network-based: a coordinate-based meta-analysis.

Authors:  F L Chiang; Q Wang; F F Yu; R S Romero; S Y Huang; P M Fox; B Tantiwongkosi; P T Fox
Journal:  Clin Radiol       Date:  2019-08-14       Impact factor: 2.350

2.  Cognitive impairment in early MS: contribution of white matter lesions, deep grey matter atrophy, and cortical atrophy.

Authors:  Christina Engl; Laura Tiemann; Sophia Grahl; Matthias Bussas; Paul Schmidt; Viola Pongratz; Achim Berthele; Annkathrin Beer; Christian Gaser; Jan S Kirschke; Claus Zimmer; Bernhard Hemmer; Mark Mühlau
Journal:  J Neurol       Date:  2020-04-23       Impact factor: 4.849

3.  Contribution of cortical lesions to cognitive impairment in Japanese patients with multiple sclerosis.

Authors:  Koji Shinoda; Takuya Matsushita; Yuri Nakamura; Katsuhisa Masaki; Shiori Sakai; Haruka Nomiyama; Osamu Togao; Akio Hiwatashi; Masaaki Niino; Noriko Isobe; Jun-Ichi Kira
Journal:  Sci Rep       Date:  2020-03-23       Impact factor: 4.379

4.  Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.

Authors:  Francisco Carlos Pérez-Miralles; Daniel Prefasi; Antonio García-Merino; José Ramón Ara; Guillermo Izquierdo; Virginia Meca-Lallana; Francisco Gascón-Giménez; María Luisa Martínez-Ginés; Lluis Ramió-Torrentà; Lucienne Costa-Frossard; Óscar Fernández; Sara Moreno-García; Jorge Maurino; Joan Carreres-Polo; Bonaventura Casanova
Journal:  Brain Behav       Date:  2021-01-23       Impact factor: 2.708

Review 5.  Recommendations for cognitive screening and management in multiple sclerosis care.

Authors:  Rosalind Kalb; Meghan Beier; Ralph Hb Benedict; Leigh Charvet; Kathleen Costello; Anthony Feinstein; Jeffrey Gingold; Yael Goverover; June Halper; Colleen Harris; Lori Kostich; Lauren Krupp; Ellen Lathi; Nicholas LaRocca; Ben Thrower; John DeLuca
Journal:  Mult Scler       Date:  2018-10-10       Impact factor: 6.312

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.